Advertisement

Neurological Sciences

, Volume 33, Supplement 1, pp 193–198 | Cite as

Triptans: over the migraine

  • D. ColognoEmail author
  • A. Mazzeo
  • B. Lecce
  • C. Mundi
  • V. Petretta
  • G. Casucci
  • F. d’Onofrio
Oral Communications

Abstract

Migraine is a chronic, recurrent, disabling condition that affects millions of people worldwide. Proper acute care treatment for migraineurs is based on triptans, a class of specific medications approved over 20 years ago. Triptans are serotonin (5-HT1B/1D) receptor agonists that are generally effective, well tolerated and safe. Seven triptans are available worldwide, although not all are available in every country, with multiple routes of administration, giving to doctors and patients a wide choice. Despite the similarities of the available triptans, pharmacological heterogeneity offers slightly different efficacy profiles. Triptans are not pain medications, they are abortive migraine medications which cannot prevent migraines. In addition to migraine attacks, triptans are also helpful for cluster headaches. If they are useful in other primary headaches rather than migraine and cluster headache it is yet to be addressed. In the literature there are only limited controlled clinical data to support a migraine-selective activity for triptans. Reports are available about efficacy of triptans to stop attacks of other types of primary headache, such as tension type headache, hypnic headache and other rare forms of primary headaches. On the other hand, sumatriptan failed to treat the indomethacin-responsive primary headache disorders like chronic paroxysmal hemicrania and hemicrania continua, nor was it effective in the myofascial temporal muscle pain or in atypical facial pain. Why triptans are effective in so different types of primary headaches remain unclear. Up to date, it is not clear whether the antimigrainous activity of the triptans involves an action only in the periphery or in the CNS as well. Probably we should consider triptans as “pain killers” and not only as “migraine killers”. We clearly need additional studies on triptans as putative analgesics in well-accepted animal and clinical models of acute and chronic somatic pain.

Keywords

Triptans Migraine Primary headache Pain 

Notes

Conflict of interest

The authors certify that there is no actual or potential conflict of interest in relation to this article.

References

  1. 1.
    Mondell BE (2003) A review of the effects of almotriptan and other triptans on clinical trial outcomes that are meaningful to patients with migraine. Clin Ther 25(2):331–341PubMedCrossRefGoogle Scholar
  2. 2.
    MacGregor EA (2010) Prevention and treatment of menstrual migraine. Drugs 70(14):1799–1818PubMedCrossRefGoogle Scholar
  3. 3.
    Allais G, Bussone G, D’Andrea G, Moschiano F, d’Onofrio F, Valguarnera F, Manzoni GC, Grazzi L, Allais R, Benedetto C, Acuto G (2011) Almotriptan 12.5 mg in menstrually related migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 31(2):144–151PubMedCrossRefGoogle Scholar
  4. 4.
    Ashkenazi A, Schwedt T (2011) Cluster headache-acute and prophylactic therapy. Headache 51:272–286PubMedCrossRefGoogle Scholar
  5. 5.
    Cady RK, Gutterman D, Saiers JA, Beach ME (1997) Responsiveness of non-IHS migraine and tension-type headache to sumatriptan. Cephalalgia 17(5):588–590PubMedCrossRefGoogle Scholar
  6. 6.
    Brennum J, Kjeldsen M, Olesen J (1992) The 5-HT1-like agonist sumatriptan has a significant effect in chronic tension-type headache. Cephalalgia 12(6):375–379PubMedCrossRefGoogle Scholar
  7. 7.
    Brennum J, Brinck T, Schriver L (1996) Sumatriptan has no clinically relevant effect in the treatment of episodic tension-type headache. Eur J Neurol 3:23–28CrossRefGoogle Scholar
  8. 8.
    Limmroth V, Kazarawa Z, Fritsche G, Diener H-C (1999) Headache after frequent use of serotonin agonists zolmitriptan and naratriptan. Lancet 353(9150):378PubMedCrossRefGoogle Scholar
  9. 9.
    Kaube H, May A, Pfaffenrath V, Diener H-C (1994) Sumatriptan misuse in daily chronic headache. BMJ 308:1573–1574PubMedCrossRefGoogle Scholar
  10. 10.
    Gsist D, Tsirpoulus I, Sindrup SH et al (1998) Inappropriate use of sumatriptan. BMJ 316:1352–1353CrossRefGoogle Scholar
  11. 11.
    Mathew N (1999) Headache after frequent triptan use. Lancet 353(9161):1363–1364PubMedCrossRefGoogle Scholar
  12. 12.
    Dekker F, Wiendels NJ, de Valk V, van der Vliet C, Knuistingh Neven A, Assendelft WJ, Ferrari MD (2011) Triptan overuse in the Dutch general population: a nationwide pharmaco-epidemiology database analysis in 6.7 million people. Cephalalgia 31(8):943–952PubMedCrossRefGoogle Scholar
  13. 13.
    Theeler BJ, Erickson JC (2012) Posttraumatic headache in military personnel and veterans of the Iraq and Afghanistan conflicts. Curr Treat Options Neurol 14(1):36–49PubMedCrossRefGoogle Scholar
  14. 14.
    Diener HC, Obermann M, Holle D (2012) Hypnic headache: clinical course and treatment. Curr Treat Options Neurol 14(1):15–26PubMedCrossRefGoogle Scholar
  15. 15.
    Schürks M, Kastrup O, Diener HC (2006) Triptan responsive hypnic headache? Eur J Neurol 13(6):666–667PubMedCrossRefGoogle Scholar
  16. 16.
    Ipekdal HI, Karadas O, Oz O, Ulas UH (2011) Can triptans safely be used for airplane headache? Neurol Sci 32(6):1165–1169PubMedCrossRefGoogle Scholar
  17. 17.
    Berilgen MS, Müngen BA (2011) New type of headache, headache associated with airplane travel: preliminary diagnostic criteria and possible mechanisms of aetiopathogenesis. Cephalalgia 31(12):1266–1273PubMedCrossRefGoogle Scholar
  18. 18.
    Basurto Ona X, Martínez García L, Solà I, Bonfill Cosp X et al (2011) Drug therapy for treating post-dural puncture headache. Cochrane Database Syst Rev 10(8):CD007887Google Scholar
  19. 19.
    Bussone G, Tullo V, d’Onofrio F, Petretta V, Curone M, Frediani F, Tonini C, Omboni S (2007) Frovatriptan for the prevention of postdural puncture headache. Cephalalgia 27(7):809–813PubMedCrossRefGoogle Scholar
  20. 20.
    Hikita T, Kodama H, Kaneko S, Amakata K, Ogita K, Mochizuki D, Kaga F, Nakamoto N, Fujii Y, Kikuchi A (2011) Sumatriptan as a treatment for cyclic vomiting syndrome: a clinical trial. Cephalalgia 31(4):504–507PubMedCrossRefGoogle Scholar
  21. 21.
    Russell G, Abu-Arafeh I, Symon DN (2002) Abdominal migraine: evidence for existence and treatment options. Paediatr Drugs 4(1):1–8PubMedGoogle Scholar
  22. 22.
    Kakisaka Y, Wakusawa K, Haginoya K, Saito A, Uematsu M, Yokoyama H, Sato T, Tsuchiya S (2010) Efficacy of sumatriptan in two pediatric cases with abdominal pain-related functional gastrointestinal disorders: does the mechanism overlap that of migraine? J Child Neurol 25(2):234–237PubMedCrossRefGoogle Scholar
  23. 23.
    Kanai A, Saito M, Hoka S (2006) Subcutaneous sumatriptan for refractory trigeminal neuralgia. Headache 46(4):577–582PubMedCrossRefGoogle Scholar
  24. 24.
    Kanai A, Suzuki A, Osawa S, Hoka S (2006) Sumatriptan alleviates pain in patients with trigeminal neuralgia. Clin J Pain 22(8):677–680PubMedCrossRefGoogle Scholar
  25. 25.
    Shimohata K, Shimohata T, Motegi R, Miyashita K (2009) Nasal sumatriptan as adjunctive therapy for idiopathic trigeminal neuralgia: report of three cases. Headache 49(5):768–770PubMedCrossRefGoogle Scholar
  26. 26.
    Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358(9294):1668–1675PubMedCrossRefGoogle Scholar
  27. 27.
    Potrebic S, Ahn AH, Skinner K, Fields HL, Basbaum AI (2003) Peptidergic nociceptors of both trigeminal and dorsal root ganglia express serotonin 1D receptors: implications for the selective antimigraine action of triptans. J Neurosci 23(34):10988–10997PubMedGoogle Scholar
  28. 28.
    Wotherspoon G, Priestley JV (2000) Expression of the 5-HT1B receptor by subtypes of rat trigeminal ganglion cells. Neuroscience 95(2):465–471PubMedCrossRefGoogle Scholar
  29. 29.
    Antonaci F, Pareja JA, Caminero AB, Sjaastad O (1998) Chronic paroxysmal hemicrania and hemicrania continua: lack of efficacy of sumatriptan. Headache 38(3):197–200PubMedCrossRefGoogle Scholar
  30. 30.
    Dao TT, Lund JP, Rémillard G, Lavigne GJ (1995) Is myofascial pain of the temporal muscles relieved by oral sumatriptan? A cross-over pilot study. Pain 62(2):241–244PubMedCrossRefGoogle Scholar
  31. 31.
    Harrison SD, Balawi SA, Feinmann C, Harris M (1997) Atypical facial pain: a double-blind placebo-controlled crossover pilot study of subcutaneous sumatriptan. Eur Neuropsychopharmacol 7(2):83–88PubMedCrossRefGoogle Scholar
  32. 32.
    Levy D, Jakubowski M, Burstein R (2004) Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc Natl Acad Sci USA 101(12):4274–4279PubMedCrossRefGoogle Scholar
  33. 33.
    Bingham S, Davey PT, Sammons M, Raval P, Overend P, Parsons AA (2001) Inhibition of inflammation-induced thermal hypersensitivity by sumatriptan through activation of 5-HT(1B/1D) receptors. Exp Neurol 167(1):65–73PubMedCrossRefGoogle Scholar
  34. 34.
    De Felice M, Ossipov MH, Wang R, Lai J, Chichorro J, Meng I, Dodick DW, Vanderah TW, Dussor G, Porreca F (2010) Triptan-induced latent sensitization: a possible basis for medication overuse headache. Ann Neurol 67(3):325–327PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • D. Cologno
    • 1
    Email author
  • A. Mazzeo
    • 1
  • B. Lecce
    • 1
  • C. Mundi
    • 2
  • V. Petretta
    • 3
  • G. Casucci
    • 4
  • F. d’Onofrio
    • 3
  1. 1.Institute of Clinical Neurophysiology, Department of NeuroscienceAzienda Ospedaliero-Universitaria “OO.RR.”FoggiaItaly
  2. 2.Neurology Unit, Department of NeuroscienceAzienda Ospedaliero-Universitaria “OO.RR.”FoggiaItaly
  3. 3.Neurology UnitHeadache CenterAvellinoItaly
  4. 4.S. Francesco Nursing HomeTelese TermeItaly

Personalised recommendations